Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist
VRXA

Veraxa Biotech AG - Post de-SPAC (VRXA) stock: insider trades, news & valuation

Health Care · Net buying
Close · Oct 9, 2026 $1.26 +15.6% on the day -88.0% over 12 months 52-week range $1.08 – $24.79

Share price and insider trades

VRXA closeInsider buyInsider sale
0102030NovDecJan 2026FebMarAprMayJunJulAugSepOctBought $82,650 on 2026-08-27 · Christoph Rudiger Antz, Oliver Rolf Baumann
Bought, 12 months$75K
Sold, 12 months$0
Insiders buying1
Insiders selling0

Veraxa Biotech AG - Post de-SPAC insider trading at a glance (Oct 9, 2026): in the past 12 months, 1 insider bought $75K and 0 sold $0 of VRXA stock on the open market.

VRXA insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q3 2026: $83K bought (2 trades)$83KQ3 2026Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0—0
Q3 2026$83K2—0

Valuation, profit and volume

P/E (trailing)n/aSector median 24.7
Market value$178MBiotechnology
Profit margin0.0%Revenue growth —
Volume vs. 50-day2.8×Last 5 sessions
Insiders' paper profit−$13KOn all tracked purchases -16.2%

Summary

Over the past 12 months, 1 Veraxa Biotech AG - Post de-SPAC insider reported open-market purchases totaling $75K, while 0 insiders reported sales totaling $0.

Insider transactions

Open-market purchases and sales.

Filed Insider Type Shares Price Value Since Score
Aug 31SEC Oliver Rolf BaumannDirector Buy 50,0005,773,618 held (+1%) $1.50 $75K -16.0% —
Aug 31SEC Christoph Rudiger AntzCEO Buy 5,000new position $1.53 $8K -17.6% —

Insiders at Veraxa Biotech AG - Post de-SPAC

InsiderBoughtSoldLast filingScore
Oliver Rolf BaumannDirector $75K — Aug 31, 2026 —
Christoph Rudiger AntzCEO $8K — Aug 31, 2026 —

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • SLBTSL Science Holding Ltd$10329.90B bought
  • KODKodiak Sciences Inc.$157M bought
  • ADRXADARx Pharmaceuticals, Inc.$87.7M bought
  • ATTOAttovia Therapeutics, Inc.$72.9M bought
  • MPLTMapLight Therapeutics, Inc.$65.5M bought
  • AVRAnteris Technologies Global Corp.$40.4M bought

VRXA stock: common questions

Are Veraxa Biotech AG - Post de-SPAC insiders buying VRXA stock?

In the past 12 months, 1 insiders reported open-market purchases of VRXA worth $75K. The latest was Director Oliver Rolf Baumann bought $75K of VRXA at $1.50 — first open-market purchase in our records.

Are Veraxa Biotech AG - Post de-SPAC insiders selling VRXA stock?

0 insiders reported sales worth $0 over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is VRXA's 52-week range?

Over the past year VRXA has traded between $1.08 and $24.79. It last closed at $1.26 on Oct 9, 2026.